Rubius Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines called Red Cell Therapeutics™. The Company's proprietary RED PLATFORM® was designed to genetically engineer and culture Red Cell Therapeutics™ that are selective, potent and off-the-shelf allogeneic cellular therapies for the potential treatment of several diseases across multiple therapeutic areas. Show more
Location: 399 Binney St Ste 300, Massachusetts, 02142-1038, US | Website: www.rubiustx.com | Industry: Research and Development in Biotechnology | Sector: Professional, Scientific, and Technical Services
Market Cap
0.00
52 Wk Range
$N/A - $N/A
Previous Close
$0.06
Open
$0.06
Volume
755,858
Day Range
$0.06 - $0.06
Enterprise Value
0.00
Cash
0.00
Avg Qtr Burn
N/A
Insider Ownership
5.50%
Institutional Own.
0.39%
Qtr Updated
09/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
RTX-240 | 4-1BBL & IL-15TP expression Details Solid tumor/s, Cancer, Non-small cell lung carcinoma, Renal cell carcinoma | Failed Discontinued | |
RTX-224 | 4-1BBL and IL-12 expression Details Solid tumor/s, Cancer | Failed Discontinued | |
RTX-321 | HPV peptide antigen expression Details Solid tumor/s, Cancer, Human papillomavirus | Failed Discontinued |